Locus 61: CYP3A5 (7q22.1)
| Meta-analysis summary statistics for associations meeting genome-wide significance |
| Lead SNP | Biochemicals | EA/OA | Ntotal | EAF | Effect (SE) | Pmeta | Details |
| rs10242455 |
X-12063 |
A/G |
6797 |
0.93 |
0.221 (0.010) |
1.67·10-109 |
show |
EA = effect allele; OA = other allele; EAF = frequency of effect allele;
| Summary of biological annotations |
| SNP | rs10242455 |
| Chromosomal location | Chr7: 99,078,115 (7q22.1) |
| Gene (distance) | CYP3A5 (-5,633) |
| Predicted causal gene | CYP3A5 |
| Gene/protein classification | metabolic enzyme |
| Metabolite (Pathway) | X-12063 (Unknown) |
| Biochemical locus-metabolite relationship | CYP3A5 encodes a P450 with 6beta-hydroxylation activity against multiple steroids [10403825]. X-12063 seems to be an unusual bile acid. |
| eQTL associations | CYP3A5 (H), CYP3A5 (F), BUD31 (L), TRIM4 (S), ZNF394 (L) † |
† F = adipose tissue; S = skin cells; L = lymphoblastoid cells; H = liver cells;
| Medical information |
| Complex trait associations | - |
| Known metabolite associations | X-12063 [23093944] |
| Inborn error of metabolism | - |
| Pharmacological information |
| ChEMBL ID | CHEMBL3019 |
| Drug information |
Substrates: Midazolam, tracolimus, erythromycin, flunitrazepa
|
| Locus information for top associated metabolite |
HapMap2 imputation | 1KGP imputation |

